中汇糖脉康干预2型糖尿病前期的临床试验

目的考察中汇糖脉康对2型糖尿病前期患者临床症状及血糖、血脂的影响。方法将72例2型糖尿病前期患者随机分为2组,中汇糖脉康组(治疗组)36例,二甲双胍组(对照组)36例。治疗组服用中汇糖脉康,对照组服用二甲双胍,疗程12周,观察受试者临床症状、空腹血糖(FPG)、餐后2h血糖(OGTT2hPG)、血清总胆固醇(TC)、三酰甘油(TG)、低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白胆固醇(HDL-C)的变化。结果治疗12周后,治疗组与对照组的血糖值均较治疗前下降(P0.05);治疗组TC、TG与治疗前相比均有所下降,HDL-C有所升高(P0.05),而对照组各项脂代谢指标无明显变化;治疗组患者各项中医临床症状与治疗前相比均有不同程度的改善,而对照组变化不明显。结论中汇糖脉康对于2型糖尿病前期疗效显著,尤其适合于糖尿病前期合并高脂血症的患者。

Clinical Trail of Zhonghui Tangmaikang in Treating Prophase Diabetes

Objective To investigate the effect of Zhonghui Tangmaikang on clinical symptom, blood sugar and lipid of pre-diabetes patients. Method Seventy-two patients of pre-diabetes were divided into 2 groups randomly (36 patients of Zhonghui Tangmaikang group, 36 patients of metformin hydrochloride group), the course of treatment was 12 weeks. The changes of clinical symptoms, FPG, OGTT 2 h PG, TC, TG, LDL-C and HDL-C of the two groups were observed. Result After treatment, the blood sugar of two groups all descend...